$APVO
Aptevo Therapeutics Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024025428 Filed on March 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.231M $2.793M $11.77M
YoY Change -9.95% -7.21% -15.15%
% of Gross Profit
Research & Development $3.752M $3.591M $17.11M
YoY Change -9.98% -23.17% -4.33%
% of Gross Profit
Depreciation & Amortization $106.0K $116.0K $567.0K
YoY Change -40.45% -27.95% -37.07%
% of Gross Profit
Operating Expenses $3.752M $6.384M $17.11M
YoY Change -9.98% -16.92% -4.33%
Operating Profit -$6.983M -$28.88M
YoY Change -9.97% 0.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $149.0K $188.0K $578.0K
YoY Change -322.39% -92.54% -114.35%
Pretax Income -$6.834M -$6.196M -$18.65M
YoY Change -474.06% 20.01% -365.9%
Income Tax
% Of Pretax Income
Net Earnings -$6.834M -$5.903M -$17.41M
YoY Change -346.45% 27.17% -316.91%
Net Earnings / Revenue
Basic Earnings Per Share -$9.95 -$1.42
Diluted Earnings Per Share -$9.95 -$11.84 -$1.42
COMMON SHARES
Basic Shares Outstanding 23.47M 17.62M 12.23M
Diluted Shares Outstanding 686.7K 12.23M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.25M $16.90M $16.90M
YoY Change -59.53% -25.32% -25.32%
Cash & Equivalents $10.25M $16.90M $13.17M
Short-Term Investments
Other Short-Term Assets $691.0K $689.0K $2.162M
YoY Change -56.32% -7.39% -6.61%
Inventory
Prepaid Expenses $1.133M $1.473M
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.07M $19.07M $19.07M
YoY Change -57.61% -30.54% -30.54%
LONG-TERM ASSETS
Property, Plant & Equipment $789.0K $895.0K $5.776M
YoY Change -38.55% -38.78% -14.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.555M $5.776M $5.776M
YoY Change -14.33% -14.62% -14.62%
TOTAL ASSETS
Total Short-Term Assets $12.07M $19.07M $19.07M
Total Long-Term Assets $5.555M $5.776M $5.776M
Total Assets $17.63M $24.84M $24.84M
YoY Change -49.59% -27.39% -27.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.720M $3.984M $3.984M
YoY Change -10.01% 13.86% 13.86%
Accrued Expenses $2.310M $2.798M $2.798M
YoY Change 88.26% 11.7% 11.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $6.298M $7.224M $7.224M
YoY Change 8.64% -17.02% -17.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $14.00K $5.397M $5.397M
YoY Change -99.76% -11.22% -11.22%
Total Long-Term Liabilities $14.00K $5.397M $5.397M
YoY Change -99.76% 270.67% -28.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.298M $7.224M $7.224M
Total Long-Term Liabilities $14.00K $5.397M $5.397M
Total Liabilities $11.53M $12.62M $12.62M
YoY Change -1.6% -22.29% -22.29%
SHAREHOLDERS EQUITY
Retained Earnings -$230.3M -$223.4M
YoY Change 13.29% 8.45%
Common Stock $236.4M $235.7M
YoY Change 4.36% 5.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.103M $12.22M $12.22M
YoY Change
Total Liabilities & Shareholders Equity $17.63M $24.84M $24.84M
YoY Change -49.59% -27.39% -27.39%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.834M -$5.903M -$17.41M
YoY Change -346.45% 27.17% -316.91%
Depreciation, Depletion And Amortization $106.0K $116.0K $567.0K
YoY Change -40.45% -27.95% -37.07%
Cash From Operating Activities -$6.651M -$5.253M -$11.73M
YoY Change -245.66% -11.55% -44.2%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $3.467M
YoY Change -71.74%
Cash From Financing Activities -3.000K 3.046M 5.998M
YoY Change -99.84% -49.22% -329.28%
NET CHANGE
Cash From Operating Activities -6.651M -5.253M -11.73M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -3.000K 3.046M 5.998M
Net Change In Cash -6.654M -2.207M -5.732M
YoY Change -347.09% -3840.68% -75.78%
FREE CASH FLOW
Cash From Operating Activities -$6.651M -$5.253M -$11.73M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$5.253M -$11.73M
YoY Change -11.55% -44.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001671584
CY2023 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
CY2022 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#RoyaltyMember
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37746
CY2023 dei Entity Registrant Name
EntityRegistrantName
APTEVO THERAPEUTICS INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1567056
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2401 4th Avenue
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98121
CY2023 dei City Area Code
CityAreaCode
206
CY2023 dei Local Phone Number
LocalPhoneNumber
838-0500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
APVO
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
11000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23472436
CY2023 dei Auditor Name
AuditorName
Moss Adams LLP
CY2023 dei Auditor Location
AuditorLocation
Seattle, WA
CY2023 dei Auditor Firm
AuditorFirmId
659
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16904000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22635000
CY2022Q4 apvo Royalty And Milestone Receivable
RoyaltyAndMilestoneReceivable
2500000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1473000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1571000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
689000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
744000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19066000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27450000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
895000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4881000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5303000
CY2023Q4 us-gaap Assets
Assets
24842000
CY2022Q4 us-gaap Assets
Assets
34215000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3984000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3499000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2098000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46303000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16904000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22636000
CY2023 apvo Warrant Modification Incremental Value
WarrantModificationIncrementalValue
2080000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6934000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1802000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
8027000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023 apvo Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures And Stock Options Exercised
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeituresAndStockOptionsExercised
-10000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6428000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
967000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2080000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2193000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17411000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12221000
CY2023 apvo Proceeds Of Warrants Issued During Period Gross
ProceedsOfWarrantsIssuedDuringPeriodGross
3300000
CY2023 apvo Warrants Issuance Costs
WarrantsIssuanceCosts
2300000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2100000
CY2023Q4 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, clinical accruals, useful lives of equipment, commitments and contingencies, stock-based compensation, and incremental borrowing rate (IBR) used for our lease. Given the global economic and geopolitical climate, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</span></p>
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000
CY2023 apvo Operating Lease Property Number Of Lab Equipment
OperatingLeasePropertyNumberOfLabEquipment
0
CY2023 apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
0
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2105000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1142000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1102000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7224000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8706000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1456000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5397000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6079000
CY2023Q4 us-gaap Liabilities
Liabilities
12621000
CY2022Q4 us-gaap Liabilities
Liabilities
16241000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19468180
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19468180
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6466294
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6466294
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
61000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235607000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
223962000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-223447000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206036000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12221000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24842000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34215000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3114000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17107000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17882000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11771000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13873000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-28878000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-28641000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
578000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4027000
CY2023 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
9650000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
37182000
CY2022 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
2500000
CY2023 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
7014000
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1239000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1013000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17411000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
8027000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.57
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.57
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12234661
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5100310
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12234661
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5102914
CY2023 us-gaap Profit Loss
ProfitLoss
-17411000
CY2022 us-gaap Profit Loss
ProfitLoss
8027000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
2193000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1802000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
567000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
901000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-47000
CY2023 apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
10000
CY2022 apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
3239000
CY2022 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
CY2023 apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-2500000
CY2022 apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-1164000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-153000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-355000
CY2023 apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
422000
CY2022 apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
653000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
518000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-394000
CY2023 apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
682000
CY2022 apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
-366000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11730000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21022000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3467000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
12267000
CY2022 apvo Repayments Under Liability Related To Sale Of Royalties
RepaymentsUnderLiabilityRelatedToSaleOfRoyalties
6779000
CY2023 apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
10000
CY2022 apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
4000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3047000
CY2022 apvo Proceeds From Milestones Related To Sale Of Royalties
ProceedsFromMilestonesRelatedToSaleOfRoyalties
10000000
CY2022 apvo Transaction Costs For Milestones Related To Sale Of Royalties
TransactionCostsForMilestonesRelatedToSaleOfRoyalties
500000
CY2023 apvo Proceeds From Issuance Of Common Stock And Prefunded Warrants
ProceedsFromIssuanceOfCommonStockAndPrefundedWarrants
6428000
CY2022 apvo Proceeds From Issuance Of Common Stock And Prefunded Warrants
ProceedsFromIssuanceOfCommonStockAndPrefundedWarrants
6934000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5998000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2616000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5732000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23667000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22636000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46303000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16904000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22636000
CY2023 apvo Warrant Modification Incremental Value
WarrantModificationIncrementalValue
2080000
CY2022 apvo Change In Rou Asset And Lease Liability From Lease Remeasurement
ChangeInROUAssetAndLeaseLiabilityFromLeaseRemeasurement
4372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1216000
CY2022 apvo Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures And Stock Options Exercised
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeituresAndStockOptionsExercised
-5000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6934000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1802000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
8027000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17974000
CY2023 apvo Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures And Stock Options Exercised
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeituresAndStockOptionsExercised
-10000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6428000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
967000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2080000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2193000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17411000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12221000
CY2023 apvo Proceeds Of Warrants Issued During Period Gross
ProceedsOfWarrantsIssuedDuringPeriodGross
3300000
CY2023 apvo Warrants Issuance Costs
WarrantsIssuanceCosts
2300000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2100000
CY2023Q4 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, clinical accruals, useful lives of equipment, commitments and contingencies, stock-based compensation, and incremental borrowing rate (IBR) used for our lease. Given the global economic and geopolitical climate, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject Aptevo to concentrations of credit risk consist primarily of cash and cash equivalents, certain investments and royalty and milestone receivable. Aptevo places its cash and cash equivalents with high quality financial institutions and may maintain cash balances in excess of insured limits. Management believes that the financial risks associated with its cash and cash equivalents are minimal.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject Aptevo to concentrations of credit risk consist primarily of cash and cash equivalents, certain investments and royalty and milestone receivable. Aptevo places its cash and cash equivalents with high quality financial institutions and may maintain cash balances in excess of insured limits. Management believes that the financial risks associated with its cash and cash equivalents are minimal.</span></p>
CY2023 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
2700000
CY2022 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
1700000
CY2023 apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2022 apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13593000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13026000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
895000
CY2023 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
523000
CY2022 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
1013000
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1239000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1013000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2023 us-gaap Depreciation
Depreciation
600000
CY2022 us-gaap Depreciation
Depreciation
900000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2023 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
523000
CY2022 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
1013000
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1239000
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1013000
CY2023 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
47500000
CY2023Q4 apvo Closing Payments Received
ClosingPaymentsReceived
35000000
CY2023 apvo Milestone Payment
MilestonePayment
12500000
CY2023 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
2700000
CY2022 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
1700000
CY2023 apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2022 apvo Research And Development Cost Percentage
ResearchAndDevelopmentCostPercentage
0.50
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13200000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21600000
CY2023 apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2023Q4 us-gaap Cash
Cash
3732000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13171000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21569000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16904000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22635000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13200000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21600000
CY2023 apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2023Q4 us-gaap Cash
Cash
3732000
CY2022Q4 us-gaap Cash
Cash
1066000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13171000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21569000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16904000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22635000
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
CY2023Q1 apvo Milestone Payment
MilestonePayment
2500000
CY2023 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
7014000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14488000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14488000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13593000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13026000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
895000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2023 us-gaap Depreciation
Depreciation
600000
CY2022 us-gaap Depreciation
Depreciation
900000
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2023 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
47500000
CY2023Q4 apvo Closing Payments Received
ClosingPaymentsReceived
35000000
CY2023 apvo Milestone Payment
MilestonePayment
12500000
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
CY2023Q1 apvo Milestone Payment
MilestonePayment
2500000
CY2021Q4 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
31045000
CY2022 apvo Milestone Payment Received Net Of Transaction Costs
MilestonePaymentReceivedNetOfTransactionCosts
9500000
CY2022 apvo Non Cash Interest Expense
NonCashInterestExpense
3416000
CY2022 us-gaap Payments For Royalties
PaymentsForRoyalties
6779000
CY2022 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
CY2021Q4 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
31045000
CY2022 apvo Milestone Payment Received Net Of Transaction Costs
MilestonePaymentReceivedNetOfTransactionCosts
9500000
CY2022 apvo Non Cash Interest Expense
NonCashInterestExpense
3416000
CY2022 us-gaap Payments For Royalties
PaymentsForRoyalties
6779000
CY2022 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
CY2023 apvo Operating Lease Property Number Of Lab Equipment
OperatingLeasePropertyNumberOfLabEquipment
0
CY2023 apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
0
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1187000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1277000
CY2023 us-gaap Lease Cost
LeaseCost
1187000
CY2022 us-gaap Lease Cost
LeaseCost
1277000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4881000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5303000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1147000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
895000
CY2023 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1239000
CY2022 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1013000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17411000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1187000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1277000
CY2023 us-gaap Lease Cost
LeaseCost
1187000
CY2022 us-gaap Lease Cost
LeaseCost
1277000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
895000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1376000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1376000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1376000
CY2023Q4 apvo Lessee Operating Lease Liability Payments Due Year Four And Beyond
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndBeyond
4587000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8715000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2636000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6079000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5400000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
700000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6100000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1376000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1376000
CY2023Q4 apvo Lessee Operating Lease Liability Payments Due Year Four And Beyond
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndBeyond
4587000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8715000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2636000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6079000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5400000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
700000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6100000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2023 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
7014000
CY2023 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1239000
CY2022 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1013000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-17411000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
8027000
CY2023 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.52
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.38
CY2023 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.52
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.37
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.1
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.2
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.1
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.2
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12234661
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5100310
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12234661
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5102914
CY2023 apvo Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P2Y9M10D
CY2023Q4 apvo Class Of Warrant Or Right Exercised With Shares Held In Abeyance
ClassOfWarrantOrRightExercisedWithSharesHeldInAbeyance
10388866
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49113000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1027000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1027000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
8027000
CY2023 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.52
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.38
CY2023 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.52
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.37
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.1
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.2
CY2023 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.1
CY2022 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.2
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12234661
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5100310
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12234661
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5102914
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
350589
CY2022Q4 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
18.2
CY2022 apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P0Y3M
CY2023 apvo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
44526070
CY2023 apvo Class Of Warrant Or Right Issued Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
0.37
CY2023 apvo Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P2Y10M20D
CY2023 apvo Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
14198518
CY2023 apvo Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.23
CY2023 apvo Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P2Y7M9D
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
30678141
CY2023Q4 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.46
CY2023 apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y11M26D
CY2023Q4 apvo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
16479623
CY2023Q4 apvo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
0.66
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
350589
CY2022Q4 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
18.2
CY2022 apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P0Y3M
CY2023 apvo Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
44526070
CY2023 apvo Class Of Warrant Or Right Issued Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice
0.37
CY2023 apvo Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P2Y10M20D
CY2023 apvo Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
14198518
CY2023 apvo Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.23
CY2023 apvo Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P2Y7M9D
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
30678141
CY2023Q4 apvo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.46
CY2023 apvo Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P2Y11M26D
CY2023Q4 apvo Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
16479623
CY2023Q4 apvo Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
0.66
CY2023 apvo Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P2Y9M10D
CY2023Q4 apvo Class Of Warrant Or Right Exercised With Shares Held In Abeyance
ClassOfWarrantOrRightExercisedWithSharesHeldInAbeyance
10388866
CY2023 apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
CY2023 apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.0401
CY2023 apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.054
CY2023Q4 apvo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1280000
CY2023 apvo Class Of Warrant Or Right Expected Dividend Yield
ClassOfWarrantOrRightExpectedDividendYield
0
CY2023 apvo Class Of Warrant Or Right Expected Volatility Rate
ClassOfWarrantOrRightExpectedVolatilityRate
1.0401
CY2023 apvo Class Of Warrant Or Right Risk Free Interest Rate
ClassOfWarrantOrRightRiskFreeInterestRate
0.054
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2193000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1802000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.68
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.36
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000
CY2022Q4 apvo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1371000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
415000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
442000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2193000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1802000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.68
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.36
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000
CY2022Q4 apvo Deferred Tax Assets Gain Related To Sale Of Future Royalties
DeferredTaxAssetsGainRelatedToSaleOfFutureRoyalties
2016000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54244000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50237000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53217000
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
7014000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7014000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35322000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
32793000
CY2023Q4 apvo Deferred Tax Assets Capitalized Research Expenditures
DeferredTaxAssetsCapitalizedResearchExpenditures
5859000
CY2022Q4 apvo Deferred Tax Assets Capitalized Research Expenditures
DeferredTaxAssetsCapitalizedResearchExpenditures
3361000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
151000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
195000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
963000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
912000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3753000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3799000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
380000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
496000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
6121000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
4852000
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.06
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
7014000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18650000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7014000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35322000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
32793000
CY2023Q4 apvo Deferred Tax Assets Capitalized Research Expenditures
DeferredTaxAssetsCapitalizedResearchExpenditures
5859000
CY2022Q4 apvo Deferred Tax Assets Capitalized Research Expenditures
DeferredTaxAssetsCapitalizedResearchExpenditures
3361000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
151000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
195000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
963000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
912000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3753000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3799000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
380000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
496000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
6121000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
4852000
CY2023Q4 apvo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1280000
CY2022Q4 apvo Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
1371000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
415000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
442000
CY2022Q4 apvo Deferred Tax Assets Gain Related To Sale Of Future Royalties
DeferredTaxAssetsGainRelatedToSaleOfFutureRoyalties
2016000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54244000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50237000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53217000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49113000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1124000
CY2023Q4 apvo Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
1027000
CY2022Q4 apvo Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
1124000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1027000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1124000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4200000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
153000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.018
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.238
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.125
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.05
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.153
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.008
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.026
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.101
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.023
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1124000
CY2023Q4 apvo Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
1027000
CY2022Q4 apvo Deferred Tax Liability Right Of Use Assets
DeferredTaxLiabilityRightOfUseAssets
1124000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1027000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1124000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4200000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
153000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.018
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.238
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.125
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.05
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.153
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.008
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.026
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.101
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.023
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000

Files In Submission

Name View Source Status
0000950170-24-025428-index-headers.html Edgar Link pending
0000950170-24-025428-index.html Edgar Link pending
0000950170-24-025428.txt Edgar Link pending
0000950170-24-025428-xbrl.zip Edgar Link pending
apvo-20231231.htm Edgar Link pending
apvo-20231231.xsd Edgar Link pending
apvo-ex21_1.htm Edgar Link pending
apvo-ex23_1.htm Edgar Link pending
apvo-ex31_1.htm Edgar Link pending
apvo-ex31_2.htm Edgar Link pending
apvo-ex32_1.htm Edgar Link pending
apvo-ex32_2.htm Edgar Link pending
apvo-ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img134589123_0.jpg Edgar Link pending
img134589123_1.jpg Edgar Link pending
img134589123_10.jpg Edgar Link pending
img134589123_11.jpg Edgar Link pending
img134589123_2.jpg Edgar Link pending
img134589123_3.jpg Edgar Link pending
img134589123_4.jpg Edgar Link pending
img134589123_5.jpg Edgar Link pending
img134589123_6.jpg Edgar Link pending
img134589123_7.jpg Edgar Link pending
img134589123_8.jpg Edgar Link pending
img134589123_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
apvo-20231231_htm.xml Edgar Link completed